Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab with nab-paclitaxel followed by pembrolizumab with epirubicin and cyclophosphamide in triple-negative breast cancer
2016-003102-14Phase 2Completed
- Sponsor
- Institut für Frauengesundheit
- Start
- May 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, paclitaxel, epirubicin and cyclophosphamide in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Institut für Frauengesundheit. Primary endpoint: Pathological complete response. Started May 2017; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2016-003102-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003102-14.